
|Articles|June 1, 2002
Terbinafine shows dose-dependency in tinea capitis
New Orleans - Dose rather than duration of therapy appears to be the important factor for achieving favorable cure rates using oral terbinafine (Lamisil) for the treatment of tinea capitis, Sheila Fallon Friedlander, M.D., said at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus
2
Del Rosso's What's New in the Medicine Chest 2026: CHE, CSU, and Vitiligo
3
Multi-Ingredient Topical Treatment Significantly Improves Wrinkles and Skin Thickness in Patients with "Ozempic Face"
4
Beyond Weight Loss: Clinical Perspectives on GLP-1s for Inflammatory Dermatoses
5










